Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford have developed a new drug delivery system using ultrasound-activated nanoparticles to break through and destroy bacterial biofilms. This offers a promising solution that could address the global crisis of chronic antibiotic-resistant infections affecting hundreds of millions of people worldwide.

The nanobubbles used in the study. © Christopher Campbell

In up to 80% of chronic infections, bacteria form biofilms – a slimy substance secreted by the bacteria which forms a protective matrix around them. Biofilms are a major contributor to antimicrobial resistance as they protect bacteria from both human immune cells and antimicrobial drugs, increasing their resistance to treatment by up to 1000-fold. Biofilms are very difficult to remove without mechanically breaking them up, which is not straightforward to do inside the body.

To address this, a team from Oxford's Department of Engineering Science and the Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS) have engineered antibiotic-loaded nanoparticles. When activated by ultrasound, these rapidly vaporise and thus both physically disrupt biofilms and release drugs directly at the infection site. Ultrasound can be precisely focused deep inside the body, which is a key advantage for targeting infections non-invasively.

Professor Eleanor StrideProfessor of Biomaterials, University of Oxford and Principal Investigator of the project, said: ‘Innovative solutions are desperately needed to extend the action of life-saving antibiotics. Our findings are very promising, as treatment of chronic infections associated with biofilm production continues to be a challenge in the face of spreading antimicrobial resistance worldwide. The methods we used in this study were designed with clinical use in mind, and we look forward to developing this system further for application in healthcare settings.'

The nanoparticles were tested against 10 clinical bacterial strains, including E. Coli and methicillin-resistant Staphylococcus aureus (MRSA), delivering four different antibiotics. With bacteria that did not form biofilms, the combination of the nanoparticles and ultrasound reduced the antibiotic concentration required to prevent their growth by more than 10-fold compared to conventional treatment.

 

Read the full story on the University of Oxford website.